Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Therapeutic Drug Carrier Systems
Импакт фактор: 2.9 5-летний Импакт фактор: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Печать: 0743-4863
ISSN Онлайн: 2162-660X

Выпуски:
Том 36, 2019 Том 35, 2018 Том 34, 2017 Том 33, 2016 Том 32, 2015 Том 31, 2014 Том 30, 2013 Том 29, 2012 Том 28, 2011 Том 27, 2010 Том 26, 2009 Том 25, 2008 Том 24, 2007 Том 23, 2006 Том 22, 2005 Том 21, 2004 Том 20, 2003 Том 19, 2002 Том 18, 2001 Том 17, 2000 Том 16, 1999 Том 15, 1998 Том 14, 1997 Том 13, 1996 Том 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i6.40
16 pages

In Vivo Applications of PEG Liposomes: Unexpected Observations

Peter Laverman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Otto C. Boerman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Wim J. G. Oyen
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Frans H. M. Corstens
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Gert Storm
Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands

Краткое описание

Recent studies with PEG liposomes in patients have consistently shown that liposomes can induce side effects (flushing, tightness of the chest). Furthermore, the blood clearance of PEG liposomes was shown to be dose-dependent: at lipid doses lower than 1 mmol/kg, PEG liposomes do not show the long-circulation property but instead are cleared relatively rapidly from the bloodstream. Another remarkable observation was that repeated injections of PEG liposomes led to significant pharmacokinetic changes: the circulatory half-life of a second dose of radiolabeled PEG liposomes dramatically decreased when given from 5 days to up to 4 weeks after a first injection. In these three unexpected phenomena, proteins of the complement system seem to play a key role.Therefore, one has to consider that PEG liposomes are not inert drug-carrying vehicles in vivo. Pharmacological effects can occur, induced solely by using liposomal particles irrespective of the drug content.


Articles with similar content:

Use of the Androgen Receptor Antagonist for the Enhancement of the Gonadotrophic Inductors of Ovulation Action in Rats with Polycystic Ovaries
International Journal of Physiology and Pathophysiology, Vol.1, 2010, issue 1
L. V. Chaikovskaya, Nadiya D. Nosenko, Larisa V. Tarasenko, Pyotr V Sinitsyn, L. I. Polyakova, Alexander G. Reznikov, Ye. N. Boris
Emerging Trends in Oral Delivery of Peptide and Protein Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 2&3
Ajit S. Narang, Laura Thoma, Duane D. Miller, Ram I. Mahato
RNA-Based Adjuvants: Immunoenhancing Effect on Antiviral Vaccines and Regulatory Considerations
Critical Reviews™ in Immunology, Vol.39, 2019, issue 1
Ulrich Kalinke, Annett Ziegler, Thomas Hinz
Pulmonary Drug Delivery Systems: Recent Developments and Prospects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 4-5
Th. F. Vandamme, N. Butz, H. M. Courrier
Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Flavio Arienti, Alessandro Borsatti, Paola Squarcina, Chiara Castelli, Filiberto Belli, Ettore Appella, Francesca Rini, Douglas J. Loftus, Francesco M. Marincola, Giorgio Parmiani, Licia Rivoltini, Carsten Geisler